| Q44119196 | A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity |
| Q27480826 | Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes |
| Q33784679 | An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. |
| Q36793253 | Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro |
| Q24647756 | Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line |
| Q33864057 | Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees |
| Q27486549 | Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques |
| Q33937698 | Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus |
| Q36868245 | Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate |
| Q34221143 | Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120 |
| Q36230737 | Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 |
| Q67524599 | Expression and gene transcript of Fc receptors for IgG, HLA class II antigens and Langerhans cells in human cervico-vaginal epithelium |
| Q37744269 | Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro |
| Q36886112 | Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge |
| Q71808669 | Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium |
| Q36795915 | Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q44194916 | Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons |
| Q67476179 | Removal of GP160 induced bio-hazards for a safe AIDS vaccine candidate |
| Q36803017 | Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals |
| Q27485986 | Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses |
| Q36793493 | Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R. |
| Q36711168 | V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1 |